1. Long-term update of the 24954 EORTC phase III trial on larynx preservation.
- Author
-
Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, and Grégoire V
- Subjects
- Adult, Aged, Carcinoma, Squamous Cell pathology, Cisplatin administration & dosage, Disease Progression, Dose Fractionation, Radiation, Female, Fluorouracil administration & dosage, Humans, Hypopharyngeal Neoplasms pathology, Laryngeal Neoplasms pathology, Laryngectomy, Male, Middle Aged, Survival Analysis, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell therapy, Chemoradiotherapy methods, Hypopharyngeal Neoplasms therapy, Laryngeal Neoplasms therapy, Larynx, Organ Sparing Treatments methods
- Abstract
The long-term results of the EORTC 24954 trial comparing sequential versus alternating chemotherapy and radiotherapy (RT) for patients with locally advanced laryngeal and hypopharyngeal cancer are reported. From 1996 to 2004, 450 patients were randomly assigned (1-1) to a sequential arm (SA = induction cisplatin-5fluorouracil followed by a 70Gy-RT for the responders or a total laryngectomy and post-operative RT for the non-responders) and an alternating arm (AA = cisplatin-5fluorouracil alternated with three 2-week courses of 20 Gy-RT for a total dose of 60 Gy). Median follow-up was 10.2 years. Ten-year survival with functional larynx (primary end-point) and overall survival were similar in both arms (18.7% and 33.6% in SA versus 18.3% and 31.6% in AA). Late toxicity was also similar; however, a trend for higher larynx preservation and better laryngeal function was observed in AA., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF